Compare TOUR & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | ICCC |
|---|---|---|
| Founded | 2006 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.1M | 75.8M |
| IPO Year | 2014 | 1995 |
| Metric | TOUR | ICCC |
|---|---|---|
| Price | $5.10 | $10.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.9K | ★ 23.9K |
| Earning Date | 06-11-2026 | 05-15-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | $17.30 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | $87.34 | ★ $49.00 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.56 | $4.52 |
| 52 Week High | $7.79 | $11.16 |
| Indicator | TOUR | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 58.26 |
| Support Level | $4.53 | $9.27 |
| Resistance Level | $6.50 | $10.75 |
| Average True Range (ATR) | 0.29 | 0.42 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 40.17 | 54.45 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.